Literature DB >> 25551679

Osteosarcoma in patients with Rothmund-Thomson syndrome.

Katja Zils1, Thomas Klingebiel, Wolfgang Behnisch, Hermann L Mueller, Paul-Gerhardt Schlegel, Michael Fruehwald, Meinolf Suttorp, Thorsten Simon, Mathias Werner, Stefan Bielack.   

Abstract

BACKGROUND: Rothmund-Thomson syndrome (RTS) is associated with an increased risk of osteosarcoma, but information about affected patients is limited. PROCEDURE: Seven patients with osteosarcoma, treated in the Cooperative Osteosarcoma Study Group-trials, had a diagnosis of RTS. Their patient-, tumor- and treatment-related variables and outcome were reviewed retrospectively.
RESULTS: Median age at diagnosis of osteosarcoma was 13 years (range 7-16), five were female, two male. Tumor involved proximal tibia (n = 4), distal tibia (n = 1), distal fibula (n = 1) and proximal ulna (n = 1). Three patients had metastatic disease at diagnosis. All patients received surgery and chemotherapy. Four of seven patients required dose modifications and three of them terminated treatment prematurely. Complete resection of the primary tumor was achieved in all individuals. Two of three affected patients failed to achieve surgical clearance of their primary metastases and died. The third patient relapsed with multiple metastases and died. Two of four patients with localized disease were alive in first complete remission, a third patient in second complete remission after recurrence and a fourth patient died of acute leukemia, while still in first complete remission of osteosarcoma.
CONCLUSIONS: Patients with RTS and osteosarcoma may be cured of their cancer with appropriate multimodal therapy. They should be treated like other osteosarcoma patients but preexisting disorders, needs for special support and development of toxicities have to be considered.

Entities:  

Keywords:  Rothmund–Thomson syndrome; cancer predisposition; chemotherapy; osteosarcoma

Mesh:

Year:  2014        PMID: 25551679     DOI: 10.3109/08880018.2014.987939

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  7 in total

1.  [Hereditary bone tumors].

Authors:  D Baumhoer
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

2.  Clinical findings, dental treatment, and improvement in quality of life for a child with Rothmund-Thomson syndrome.

Authors:  Katharina Morant Holanda De Oliveira; Raquel Assed Bezerra Silva; Fabricio Kitazono Carvalho; Lea Assed Bezerra Silva; Paulo Nelson-Filho; Alexandra Mussolino Queiroz
Journal:  Contemp Clin Dent       Date:  2016 Apr-Jun

3.  Rothmund-Thomson Syndrome: novel pathogenic mutations and frequencies of variants in the RECQL4 and USB1 (C16orf57) gene.

Authors:  Aude-Annick Suter; Peter Itin; Karl Heinimann; Munaza Ahmed; Tazeen Ashraf; Helen Fryssira; Usha Kini; Pablo Lapunzina; Peter Miny; Mette Sommerlund; Mohnish Suri; Signe Vaeth; Pradeep Vasudevan; Sabina Gallati
Journal:  Mol Genet Genomic Med       Date:  2016-02-24       Impact factor: 2.183

4.  Somatic and germline analysis of a familial Rothmund-Thomson syndrome in two siblings with osteosarcoma.

Authors:  Miriam Gutiérrez-Jimeno; Elena Panizo-Morgado; Ibon Tamayo; Mikel San Julián; Ana Catalán-Lambán; Marta M Alonso; Ana Patiño-García
Journal:  NPJ Genom Med       Date:  2020-12-04       Impact factor: 8.617

Review 5.  Timing of treatment in osteosarcoma: challenges and perspectives - a scoping review.

Authors:  Michael S Kim; Ioanna K Bolia; Brenda Iglesias; Tamara Sharf; Sidney I Roberts; Hyunwoo Kang; Alexander B Christ; Lawrence R Menendez
Journal:  BMC Cancer       Date:  2022-09-10       Impact factor: 4.638

6.  Multiple Low Energy Long Bone Fractures in the Setting of Rothmund-Thomson Syndrome.

Authors:  Nicholas Beckmann
Journal:  Case Rep Med       Date:  2015-11-05

Review 7.  Genetic Predisposition to Solid Pediatric Cancers.

Authors:  Mario Capasso; Annalaura Montella; Matilde Tirelli; Teresa Maiorino; Sueva Cantalupo; Achille Iolascon
Journal:  Front Oncol       Date:  2020-10-28       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.